Glucosylceramide Synthase Inhibitors for Gaucher Disease and Niemann-Pick Disease (Elelyso, Cerdelga, Cerezyme, VPRIV, and miglustat/Yargesa/Zavesca)
Customize your policy alerts
Sign up for blue cross blue shield - south dakota Policy 05.02.42 alerts
Get alerted when Policy 05.02.42 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage, prior authorization, preferred-product requirements, medical-necessity criteria, continuation criteria, and dosing or quantity limits for therapies used to treat type 1 or type 3 Gaucher disease and Niemann-Pick disease type C.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.